← All Allovir, INC filings

Allovir, INC Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

ALVR
Allovir, INC
SCHEDULE: Samsara BioCapital Adjusts Kalaris Therapeutics Stake
Samsara BioCapital reports internal share transfers and distributions among its affiliated funds regarding Kalaris Therapeutics.
ALVR
Allovir, INC
SCHEDULE: Samsara BioCapital Boosts Kalaris Therapeutics Stake to 56.5%
Samsara BioCapital and its affiliates, led by Srinivas Akkaraju, increased their beneficial ownership in Kalaris Therapeutics to 56.5% following a $15 million investment in a private placement.
ALVR
Allovir, INC
SCHEDULE 13D: Samsara BioCapital Discloses 61.2% Stake in Kalaris Therapeutics Following Merger
Samsara BioCapital, L.P., along with its general partner and managing member, has reported beneficial ownership of 61.2% of Kalaris Therapeutics, Inc. common stock following a recent merger.